News

Australia’s system for deciding whether new health technologies are funded is too focused on contested models and not enough on real people and their needs. The lack of human consideration leads to long delays, avoidable suffering, and sometimes deaths, in a process where patient voices are 'summarised' into oblivion while insiders talk around the problem instead of fixing it quickly, openly, and based on our shared values.

Despite widely held perceptions in countries like Australia and New Zealand, a new survey reveals that almost 9 in 10 Americans would prefer to be treated in the U.S. if they developed an illness.

How often does any document produced on Australia's use of this stuff start by describing its institutional frameworks as 'world class'? As a self-affirming statement of objective fact, its sole practical impact is to undermine and invalidate any call for change.

Wholesale distribution strengthened through new customer acquisitions, higher volumes from existing pharmacy partners and continued demand in high-value drug categories, including weight-loss treatments.

Telix Pharmaceuticals (ASX:TLX) has taken another step in expanding its neuro-oncology portfolio, announcing the submission of a European marketing authorisation application for its brain cancer imaging candidate TLX101-Px.

Australian pharmaceutical manufacturer IDT says it is beginning to show tangible signs of recovery after a period of leadership change and financial pressure, reporting improved earnings and renewed operational momentum in the first half of the financial year 2026.

Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development.

Australia’s life sciences sector is set for a stronger, more coordinated innovation pipeline following a new national partnership between industry body AusBiotech and biomedical venture creator Proto Axiom.

The program is funded by Novo Nordisk through its 'Cities for Better Health' initiative, which partners with cities worldwide to tackle chronic disease through prevention and healthier urban living.

CSL has taken another step in its push to expand its portfolio of innovative therapies, announcing a new licensing agreement with Eli Lilly that could broaden the future reach of its monoclonal antibody candidate, clazakizumab.

People in New Zealand living with chronic lymphocytic leukaemia may soon gain funded access to modern targeted therapies under a new proposal from Pharmac.

Percheron Therapeutics (ASX:PER) is positioning itself as a small but strategically focused biotechnology company seeking to carve out a role in the rapidly expanding immuno-oncology market.